| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/14728210903405619 |
| P698 | PubMed publication ID | 20055689 |
| P2093 | author name string | Rosanna Abbate | |
| Serafina Valente | |||
| Chiara Lazzeri | |||
| Roberto Tarquini | |||
| G F Gensini | |||
| P2860 | cites work | Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators. | Q53367479 |
| The Hyperglycemia: Intensive Insulin Infusion in Infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction. | Q53727713 | ||
| Abciximab as Adjunctive Therapy to Reperfusion in Acute ST-Segment Elevation Myocardial Infarction | Q56944163 | ||
| Comparison of benefits and complications of hirudin versus heparin for patients with acute coronary syndromes undergoing early percutaneous coronary intervention | Q56944673 | ||
| ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention—Summary Article | Q56986819 | ||
| ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European S | Q58973291 | ||
| Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology: | Q22242896 | ||
| Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction | Q24683044 | ||
| Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial | Q28193186 | ||
| Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin | Q28200091 | ||
| Clinical aspects of platelet inhibitors and thrombus formation | Q28210313 | ||
| Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial | Q28211092 | ||
| A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease | Q28213238 | ||
| Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation | Q28218789 | ||
| Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial | Q28256871 | ||
| Bivalirudin during primary PCI in acute myocardial infarction | Q28281179 | ||
| Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial | Q28300233 | ||
| The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase | Q28373346 | ||
| Ticagrelor versus clopidogrel in patients with acute coronary syndromes | Q29619002 | ||
| Primary PCI for myocardial infarction with ST-segment elevation | Q30442496 | ||
| A randomized double-blind trial of intravenous trimetazidine as adjunctive therapy to primary angioplasty for acute myocardial infarction. | Q31966140 | ||
| Refractory no-reflow successfully treated with local infusion of high-dose adenosine and verapamil--a case report | Q32066885 | ||
| Recognition, treatment, and prevention of heparin-induced thrombocytopenia: review and update | Q33368280 | ||
| Clinical practice. Heparin-induced thrombocytopenia | Q33372371 | ||
| Stem cells improve left ventricular function in acute myocardial infarction. | Q33428042 | ||
| Hotlines and clinical trial updates presented at the European Society of Cardiology Meeting 2009: data from RE-LY, PLATO, MADIT-CRT, PROTECT, SYNTAX, TRITON and more | Q33506115 | ||
| Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview | Q33860081 | ||
| Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. | Q33872047 | ||
| Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study | Q34009506 | ||
| Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction | Q34168972 | ||
| Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy | Q34350556 | ||
| Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour | Q34398044 | ||
| A population-based study of the drug interaction between proton pump inhibitors and clopidogrel | Q34603772 | ||
| ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the M | Q34649834 | ||
| Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and | Q34775547 | ||
| ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology | Q34830023 | ||
| Genetic determinants of response to clopidogrel and cardiovascular events | Q34910210 | ||
| Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome | Q34956075 | ||
| Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm | Q35160529 | ||
| Society of cardiac angiography and interventions: Suggested management of the no‐reflow phenomenon in the cardiac catheterization laboratory | Q35546872 | ||
| 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evide | Q37031817 | ||
| The pathogenesis and treatment of no-reflow occurring during percutaneous coronary intervention | Q37060929 | ||
| Late sodium current inhibition as a new cardioprotective approach | Q37156945 | ||
| Hyperglycaemia in acute coronary syndromes: risk-marker or therapeutic target? | Q37242193 | ||
| A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines? | Q37377110 | ||
| Orphan targets for reperfusion injury. | Q37436743 | ||
| Aggressive chronic platelet inhibition with prasugrel and increased cancer risks: revising oral antiplatelet regimens? | Q37509176 | ||
| Management of cardiogenic shock: focus on tissue perfusion | Q37547340 | ||
| Adjunctive low molecular weight heparin during fibrinolytic therapy in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized control trials. | Q37554115 | ||
| P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. | Q37562606 | ||
| Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials | Q37590925 | ||
| Sodium-hydrogen exchange inhibition by cariporide to reduce the risk of ischemic cardiac events in patients undergoing coronary artery bypass grafting: results of the EXPEDITION study | Q38501716 | ||
| Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review | Q38554587 | ||
| Indications for implantable cardioverter-defibrillators based on evidence and judgment | Q39953794 | ||
| Usefulness of intra-aortic balloon pump counterpulsation in patients with cardiogenic shock from acute myocardial infarction | Q39962044 | ||
| Glucose normalization and outcomes in patients with acute myocardial infarction | Q39996366 | ||
| Results of the first clinical study of adjunctive CAldaret (MCC-135) in patients undergoing primary percutaneous coronary intervention for ST-Elevation Myocardial Infarction: the randomized multicentre CASTEMI study | Q40280772 | ||
| The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties | Q41906079 | ||
| ??? | Q28222150 | ||
| Prevention of myocardial enzyme release by ranolazine in a primate model of ischaemia with reperfusion | Q41967273 | ||
| The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin | Q42049501 | ||
| Intracoronary versus intravenous abciximab in ST-segment elevation myocardial infarction: rationale and design of the CICERO trial in patients undergoing primary percutaneous coronary intervention with thrombus aspiration | Q42590257 | ||
| Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial | Q42614551 | ||
| Ticagrelor--is there need for a new player in the antiplatelet-therapy field? | Q43283545 | ||
| Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial | Q43283673 | ||
| Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes | Q43445863 | ||
| Use of the percutaneous left ventricular assist device in patients with severe refractory cardiogenic shock as a bridge to long-term left ventricular assist device implantation. | Q43509133 | ||
| P2y(12), a new platelet ADP receptor, target of clopidogrel | Q43591480 | ||
| Low-dose glucose-insulin-potassium is ineffective in acute myocardial infarction: results of a randomized multicenter Pol-GIK trial | Q43625417 | ||
| The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial | Q43796510 | ||
| Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand | Q43811969 | ||
| Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. | Q44074134 | ||
| Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction | Q44128296 | ||
| No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention | Q44270415 | ||
| Blockade of the platelet P2Y12 receptor by AR-C69931MX sustains coronary artery recanalization and improves the myocardial tissue perfusion in a canine thrombosis model | Q44316947 | ||
| Cardioprotective effect of trimetazidine during thrombolytic therapy in patients with acute myocardial infarction. | Q44379335 | ||
| Glucose-insulin-potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomized trial | Q44574635 | ||
| Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity | Q44642265 | ||
| A randomized evaluation of the effects of glucose-insulin-potassium infusion on myocardial salvage in patients with acute myocardial infarction treated with reperfusion therapy | Q44950894 | ||
| Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial | Q45238837 | ||
| Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Tr | Q46038950 | ||
| Platelet inhibition with prasugrel and increased cancer risks: potential causes and implications | Q46046440 | ||
| Ischemia detected on continuous electrocardiography after acute coronary syndrome: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis In Myocardial In | Q46048410 | ||
| Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial | Q46105774 | ||
| Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up | Q46178120 | ||
| Time of onset and outcome of cardiogenic shock in acute coronary syndromes | Q46252624 | ||
| Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients | Q46338658 | ||
| Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors | Q46373411 | ||
| Short-term bridge to heart transplant using the BVS 5000 external ventricular assist device. | Q46432954 | ||
| Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction | Q46457030 | ||
| A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). | Q46528602 | ||
| Metabolic management of acute myocardial infarction comes to the fore and extends beyond control of hyperglycemia | Q46621659 | ||
| Impact of reversibility of no reflow phenomenon on 30-day mortality following percutaneous revascularization for acute myocardial infarction-insights from a 1,328 patient registry | Q46662897 | ||
| Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc | Q46868498 | ||
| Prasugrel versus clopidogrel in patients with acute coronary syndromes | Q46915044 | ||
| Cardiac mitochondrial alterations induced by insulin deficiency and hyperinsulinaemia in rats: targeting membrane homeostasis with trimetazidine | Q46918342 | ||
| Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials | Q46928598 | ||
| Suppression of angioplasty-related inflammation by pre-procedural treatment with trimetazidine | Q46960760 | ||
| Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock | Q46983271 | ||
| Fondaparinux in ST-segment elevation myocardial infarction: the drug, the strategy, the environment, or all of the above? | Q46990598 | ||
| Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. | Q48887708 | ||
| The disposition of prasugrel, a novel thienopyridine, in humans. | Q50700156 | ||
| Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. | Q51535796 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | myocardial infarction | Q12152 |
| P304 | page(s) | 87-105 | |
| P577 | publication date | 2010-03-01 | |
| P1433 | published in | Expert Opinion on Emerging Drugs | Q5421207 |
| P1476 | title | Emerging drugs for acute myocardial infarction | |
| P478 | volume | 15 |
Search more.